Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer

Tumori. 2008 Jul-Aug;94(4):624-6. doi: 10.1177/030089160809400436.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Biomarkers / metabolism
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Carcinoma / drug therapy*
  • Carcinoma / metabolism*
  • Cisplatin / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Gemcitabine
  • Humans
  • Intestinal Mucosa / metabolism*
  • Irinotecan
  • Lactulose / blood
  • Lactulose / metabolism*
  • Lactulose / urine
  • Leucovorin / administration & dosage
  • Mannitol / blood
  • Mannitol / metabolism*
  • Mannitol / urine
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism*
  • Permeability
  • Topotecan / administration & dosage

Substances

  • Biomarkers
  • Deoxycytidine
  • Mannitol
  • Lactulose
  • Irinotecan
  • Topotecan
  • Cisplatin
  • Leucovorin
  • Fluorouracil
  • Camptothecin
  • Gemcitabine